Literature DB >> 19245390

One or several types of triptan overuse headaches?

Christelle Créac'h1, Francoise Radat, Gerard Mick, Evelyne Guegan-Massardier, Pierric Giraud, Nathalie Guy, Nelly Fabre, Fatima Nachit-Ouinekh, Michel Lanteri-Minet.   

Abstract

BACKGROUND: Whereas the clinical features of pure triptan overuse headache (TOH) are well known, there are insufficient data regarding the semiological pattern of headaches when triptan overuse is associated with other types of medication overuse.
OBJECTIVE: To investigate and compare the clinical characteristics of patients with pure TOH and those with medication overuse headaches associating triptan and other medication overuses (combined TOH).
METHODS: This cross-sectional, observational study was conducted in 7 tertiary-care headache centers participating in the French Observatory of Migraine and Headaches. From 2004 to 2006, data from 163 patients with TOH were collected in face-to-face structured interviews (according to the International Classification of Headache Disorders, 2nd edition criteria).
RESULTS: Eighty-two patients fulfilled criteria for pure TOH (pTOH patients) and 81 for combined TOH (cTOH) patients. Continuous headaches were reported in 76% of cTOH patients compared with 32% of pTOH patients. Significantly more frequent and severe headaches and more intense phono-/photophobia between attacks were noted in cTOH patients. More cTOH than pTOH patients reported a history of tension-type headaches and a long-standing history of chronic headaches. Finally, compared with pTOH patients, cTOH patients were characterized by stronger dependence on acute treatments of headaches according to the DSM-IV criteria.
CONCLUSIONS: Combined therapy with analgesics and/or the total number of drug units taken per day may cause a shift from a pattern of clear-cut headache attacks in patients with pTOH toward more severe clinical presentation in patients with cTOH. These patients should receive more intensive prophylactic therapy and specific behavioral management.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19245390     DOI: 10.1111/j.1526-4610.2009.01365.x

Source DB:  PubMed          Journal:  Headache        ISSN: 0017-8748            Impact factor:   5.887


  6 in total

Review 1.  Medication overuse headache.

Authors:  Valerie Cheung; Farnaz Amoozegar; Esma Dilli
Journal:  Curr Neurol Neurosci Rep       Date:  2015-01       Impact factor: 5.081

2.  Drug dependence associated with triptans and ergot derivatives: a case/non-case study.

Authors:  Frédérique Beau-Salinas; Annie Pierre Jonville-Béra; Haware Cissoko; Lamiae Bensouda-Grimaldi; Elisabeth Autret-Leca
Journal:  Eur J Clin Pharmacol       Date:  2009-12-19       Impact factor: 2.953

Review 3.  Medication-overuse headache: risk factors, pathophysiology and management.

Authors:  Hans-Christoph Diener; Dagny Holle; Kasja Solbach; Charly Gaul
Journal:  Nat Rev Neurol       Date:  2016-09-12       Impact factor: 42.937

Review 4.  Medication-overuse headache: a review.

Authors:  Espen Saxhaug Kristoffersen; Christofer Lundqvist
Journal:  J Pain Res       Date:  2014-06-26       Impact factor: 3.133

5.  Management of medication overuse (MO) and medication overuse headache (MOH) S1 guideline.

Authors:  Hans-Christoph Diener; Peter Kropp; Thomas Dresler; Stefan Evers; Stefanie Förderreuther; Charly Gaul; Dagny Holle-Lee; Arne May; Uwe Niederberger; Sabrina Moll; Christoph Schankin; Christian Lampl
Journal:  Neurol Res Pract       Date:  2022-08-29

6.  Economic impact of a triptan Rx-to-OTC switch in six EU countries.

Authors:  Aurelie Millier; Joshua Cohen; Mondher Toumi
Journal:  PLoS One       Date:  2013-12-19       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.